MedRhythms initiates clinical trial of PD targeted digital therapeutic

Recognized for developing direct stimulation solutions based on clinical-grade sensors, software and music, digital therapeutics company, MedRhythms has confirmed the initiation of a multi-site clinical trial of its pipeline asset, MR-005, for Parkinsons disease (PD) in unison with the Boston University.

Adding to this, the company has also confirmed on expanding its pipeline into therapeutics for aging with the development of Aging SAB (Scientific Advisory Board). Incidentally, these developments come in line with MedRhythms' announcement on furthering its pipeline into multiple sclerosis (MS) and PD in 2020, with the commencement of clinical trials and the development of PD and MS SABs.

According to Dr. Terry Ellis, Chair of the Dept. of Physical Therapy & Athletic Training, Boston University College of Health & Rehabilitation Sciences, MedRhythms’ product has vast potential to aid people suffering from Parkinson's disease who require more options for interventions to enhance their walking ability.

Music, Rhythmic Auditory Stimulation in particular, is a promising intervention for Parkinson's disease patients, as it has shown evidence to better improve gait and reduce falls in this patient population over decades. As a digital therapeutic for PD walking impairments, MR-005 offers an opportunity for the intervention to be provided at scale, and Boston University is excited to be a part of this development.

The recent trial follows MedRhythms' prior initiated study in chronic stroke and MS. To elaborate, the chronic stroke trial was an 8-center randomized controlled study and MedRhythms' pivotal trial for this asset. Whereas the MS trial was a feasibility study at Cleveland Clinic.

Brian Harris, CEO & Co-Founder, MedRhythms, said that as their firm expands its pipeline into new populations, it is honored to ally with some of the world's leading minds to reach its goal and provide crucial healthcare in areas with high unmet needs.

Source Credit: